Home / Procedures / Dermal Fillers / Treatment areas

Treatment areas

Treatment areas

Each treatment area is named on a product approval. FDA approves a product area by area, so the same product may be approved for one area and not another.

Products

Area by area

Where filler is injected

1. Nasolabial folds

The lines from the sides of the nose to the corners of the mouth. The first approved use of Restylane (2003), Juvederm (2006), Radiesse (2006), ArteFill (2006), Belotero Balance (2011) and RHA (2017). In 2025 ASPS data, facial rejuvenation was 70 percent of hyaluronic acid filler treatments.[1][2][3]

2. Lips

FDA-approved for lip augmentation: Restylane (2011) and Juvederm Volbella XC (2016). In the Volbella trial, 80.3% of 152 subjects gained at least 1 point of lip fullness at month 3, and 61.8% held improvement through 1 year. Lip augmentation was 23 percent of hyaluronic acid filler treatments in 2025.[1][2][3]

3. Cheeks and midface

FDA-approved for deep injection: Juvederm Voluma XC (2013) and Restylane Lyft (2015). In the Voluma trial, 85.6% were responders at month 6 and 67% at 24 months, at a mean volume of 6.8 mL.[1][2][3]

4. Under-eye hollows (tear troughs)

The FDA general filler page lists the area around the eyes among unapproved uses. Specific products have since been approved for infraorbital hollows: Juvederm Volbella XC (2021) and Restylane Eyelight (2023). In the Eyelight trial of 333 participants, the responder rate was 69.7 percentage points higher than no treatment at 3 months, with effect through 12 months.[1][2][3]

5. Chin

FDA-approved for Juvederm Voluma XC in 2020 and Restylane Lyft in 2025. In the Voluma chin trial, investigators rated 91.2% of treated subjects improved at month 6, against 19.5% of untreated controls.[1][2][3]

6. Jawline

FDA-approved for Juvederm Volux XC in 2022. In the Volux trial of 271 patients, 89% had aesthetic improvement at 6 months and 80% at 1 year. Maintenance treatment at 1 year used less than half the original volume.[1][2]

7. Back of the hands

FDA-approved for Radiesse on June 4, 2015, to correct volume loss on the back of the hand. FDA lists difficulty performing activities as a common risk seen only after hand injection.[1][2]